Hu, Y., Xiao, L., Yang, N., & Zhang, Y. (2019). Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient. Thorac Cancer.
Chicago ZitierstilHu, Yijuan, Lili Xiao, Nong Yang, und Yongchang Zhang. "Tyrosine Kinase Inhibitor Acquired Resistance Mechanism Alternates between EGFR and ALK in a Lung Adenocarcinoma Patient." Thorac Cancer 2019.
MLA ZitierstilHu, Yijuan, Lili Xiao, Nong Yang, und Yongchang Zhang. "Tyrosine Kinase Inhibitor Acquired Resistance Mechanism Alternates between EGFR and ALK in a Lung Adenocarcinoma Patient." Thorac Cancer 2019.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.